Abstract:Two series of novel naphthalin-containing pyrazoline derivatives C1–C14 and D1–D14 have been synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. Compound D14 displayed the most potent activity against EGFR and A549 cell line (IC50=0.05μM and GI50=0.11μM), being comparable with the positive control Erlotinib (IC50=0.03μM and GI50=0.03μM) and more potent than our previous compounds C0–A (IC50=5.31μM and GI50=33.47μM) and C0–B (IC50=0.09μM and GI50=0.34μM). Meanwhile, compound C14 displayed the most potent activity against HER-2 and MCF-7 cell line (IC50=0.88μM and GI50=0.35μM), being a little less potent than Erlotinib (IC50=0.16μM and GI50=0.08μM) but far more potent than C0–A (IC50=6.58μM and GI50=27.62μM) and C0–B (IC50=2.77μM and GI50=3.79μM). The docking simulation was performed to analyze the probable binding models and the QSAR models were built for reasonable design of EGFR/HER-2 inhibitors at present and in future. The structural modification of introducing naphthalin moiety reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity. Moreover, the replacement of thiourea skeleton by using benzene ring resulted in the slight diversity of the two series towards specific targets.

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Synthesis, biological evaluation, and molecular docking studies of pyrazolyl-acylhydrazone derivatives as novel anticancer agents

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Synthesis, Molecular Docking and Antitumor Activity of New Dithiazoles

Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Synthesis, Molecular Modeling and Biological Evaluation of N-benzylidene-2-((5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl)thio)acetohydrazide Derivatives As Potential Anticancer Agents

Synthesis, Molecular Docking and Evaluation of Thiazolyl-Pyrazoline Derivatives As Egfr Tk Inhibitors and Potential Anticancer Agents

Synthesis and Biological Evaluation of Compounds Which Contain Pyrazole, Thiazole and Naphthalene Ring As Antitumor Agents.

Design, Synthesis and Biological Evaluation of Pyrazolyl-Thiazolinone Derivatives As Potential EGFR and HER-2 Kinase Inhibitors

Synthesis, Biological Evaluation, and Molecular Docking Studies of 2-Chloropyridine Derivatives Possessing 1,3,4-Oxadiazole Moiety As Potential Antitumor Agents

Synthesis, In Vitro Evaluation and Molecular Docking Studies of Novel Thiophenyl Thiazolyl-Pyridine Hybrids as Potential Anticancer Agents

Synthesis and Cytotoxic Activity of Some Novel N-Pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide Derivatives

Synthesis, Biological Evaluation, and Molecular Docking Studies of Diacylhydrazine Derivatives Possessing 1,4-Benzodioxan Moiety As Potential Anticancer Agents

Design And Synthesis Of Novel Thiazole Linked Tetrahydropyridine Analogues As Anticancer Agents

Novel 3-(2-(3-methyl-5-substituted-phenyl-4,5-dihydropyrazol-1-yl)-2-oxoethoxy)-2-substituted-phenyl-4H-chromen-4-one: synthesis and anticancer activity.

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents

Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents.

Synthesis, Biological Evaluation and Molecular Docking Studies of 1,3,4-Thiadiazole Derivatives Containing 1,4-Benzodioxan As Potential Antitumor Agents

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.